Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Nov-Dec;65(6):522-525.
doi: 10.4103/ijd.IJD_481_20.

Hand-Foot Skin Reaction with Sunitinib: A Rare Case Report with Review of Literature

Suchibrata Das  1 , Alok K Roy  1 , Srutee Barman  1 , Aritra Roy  1
Affiliations
Case Reports

Hand-Foot Skin Reaction with Sunitinib: A Rare Case Report with Review of Literature

Suchibrata Das et al. Indian J Dermatol. 2020 Nov-Dec.

Abstract

Newer multi-kinase inhibitors (MKI) like sunitinib have changed the therapy of patients of renal cell carcinoma, hepatocellular carcinoma, and gastrointestinal stromal tumor. The use of sunitinib also led to cutaneous toxicity, known as hand-foot skin reaction (HFSR). We report a case of hand-foot skin reaction (HFSR) in an Indian patient being treated with sunitinib. Respective literature on this disorder is also reviewed.

Keywords: Adverse cutaneous drug reactions; hand-foot skin reaction; kinase inhibitors; sunitinib.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
a,b- Yellow-colored callus-like hyperkeratotic plaques. c- Blisters are on side of 2nd toes and dorsum of one foot. d- Blister surrounded by erythema
Figure 2
Figure 2
a- Hyperkeratotic plaques. b - Erythema on finger tips. c- Ulcerated and crusted lesions on extensor of elbows. d- Angular cheilitis
Figure 3
Figure 3
a- Subsiding hyperkeratotic lesion and erythema. b- Subsiding crusted lesion. c- Subsiding hyperkeratotic lesion. d- Subsiding blister lesion, leaving minimal change. e- Crusted healed lesion at lower back
See this image and copyright information in PMC

References

    1. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9:327–37. - PubMed
    1. Rock EP, Goodman V, Jiang JX, Mahjoob K, Verbois SL, Morse D, et al. Food and drug administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist. 2007;12:107–13. - PubMed
    1. Lipworth AD, Robert C, Zhu AX. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology. 2009;77:257–71. - PubMed
    1. Yang CH, Lin WC, Chuang CK, Chang YC, Pang ST, Lin YC, et al. Hand-foot skin reaction in patients treated with sorafenib: A clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol. 2008;158:592–6. - PubMed
    1. Iacovelli R, Mancini ML, Risi E, Palazzo A, Cortesi E. Genital and inguinal cutaneous toxicity in male and female patients treated with Sunitinib. Int J Dermatol. 2012;51:221–2. - PubMed

Publication types